AlzeCure Pharma (ALZCUR) Study update summary

Unmet Medical Need and Market Opportunity

• Osteoarthritis (OA) and chemotherapy-induced neuropathic pain affect large, growing populations with significant unmet needs due to limited efficacy and safety of current treatments.

• OA affects over 500 million people globally, with the market valued at $10 billion and expected to grow 5%-9% annually.

• The OA market is projected to grow from $7.3 billion in 2020 to $11.0 billion by 2025.

• Current therapies, including NSAIDs and opioids, have limited efficacy and substantial side effects, especially in elderly patients.

• Chemotherapy-induced neuropathic pain is increasing due to improved cancer survival rates, with current treatments offering poor efficacy.

Background and Rationale

• NGF and its receptor TrkA are key mediators in pain sensation, validated genetically and clinically in humans.

• Deletion of NGF or TrkA leads to a painless phenotype, highlighting their role in pain signaling.

• Anti-NGF antibodies have shown efficacy in pain but are limited by adverse events.

• TrkA is a validated target for pain treatment, with allosteric modulators offering potential for biased signaling.

Evolution of Pain Therapies Targeting NGF/TrkA

• First-generation non-selective Trk inhibitors targeted multiple Trk receptors.

• Second-generation anti-NGF monoclonal antibodies blocked NGF and pro-NGF signaling but caused dose-limiting side effects.

• Third-generation negative allosteric modulators (NAMs) selectively inhibit TrkA, aiming for improved safety and efficacy.